Research Services
Disease animal model
Psychiatric & meurological disease models
Cardiovascular disease model
Respiratory disease model
Endocrine system disease model
Digestive system models
Urinary system disease model
Bone-related disease model
Oral disease models
Reproductive system disease model
Skin-related disease models
Animal models of other diseases
Pathological and biochemical omics analysis
Blood and urine biochemical analysis
Pathological examination
Immunohistochemistry
Metabolite detection
Proteomics experiment
Gene transcriptome analysis
Cellular and molecular protein experiment
Cell isolation and culture
Cell transfection
Cellular drug treatment
Cellular function assay
Flow cytometry
Molecular protein immunoassay
Imaging-based assessment of animal behavior
Learning and memory behavioral science
Anxiety and depression behavioral science
Neuropsychiatric
In vivo imaging
Micro-CT scanning
Analysis of animals’ alertness and physical constitution
Contract breeding, contract rearing, and purification
Experimental mouse breeding and husbandry services
Laboratory mouse purification
Rapid propagation
Genetic material conservation and revival
Laboratory animal support services
Domestic transportation of laboratory animals
Import and export of laboratory animals and cells
Preclinical CRO
Efficacy Evaluation
Drug screening
Effectiveness evaluation
Safety assessment
Pharmacokinetics
Preclinical research on stem cells
Evaluation of medical devices and nanomaterials
Disease Animal Model
Psychiatric & neurological disease models
Contract Breeding, Contract Rearing, And Purification
Laboratory Animals
Best-selling laboratory mouse strains
Standard laboratory mouse strains
Disease model mice
Other animal models
Gene-edited mouse
Tool mouse
Resource center
Transportation and import-export business
CRISPR Library Screening
In Vivo Screen
In Vitro Screen
In Silico Library Screening
Insight
Latest News
Technical Column
Service Cases
Marketing Campaign
About
Company Overview
Platform
Customer Feedback
Contact Us
Focusing on cutting-edge technologies and research advancements, sharing Aniphe BioLab’s achievements in scientific innovation, Professional insights and practical experience in the fields of laboratory animals and preclinical research.
Publish an article
2026-10-29
Naming Genetically Engineered Mice (Part II): From Being Understandable to Being Written Correctly
How should a multi-disease composite mouse model be constructed? Let’s take a look at the CKM approach.
2026-08-12
2026 CKM Guidelines Released: Chronic Diseases Enter the Era of Integrated Cardiorenal-Metabolic Management—It’s Time to Rethink Animal Models
A Guide to Safe Mouse Handling | Manual on Mouse Transport Protocols and Troubleshooting
2026/05/29
Chronic Stress-Induced Depression Model Platform: CUMS/CSDS/CRS/SIS—customizable on demand, supporting the development of novel therapeutics for psychiatric disorders.
Depression is a common mental disorder whose principal clinical features include anhedonia, diminished motivation, cognitive deficits, and depressed mood. Genetic factors account for approximately 40% of depressive cases, with the remainder attributable to environmental influences. Chronic stress responses triggered by environmental risk factors can mediate the development of depression. To better elucidate the pathophysiological mechanisms of depression and to identify therapeutic strategies, it is essential to establish an effective animal model of the disorder.
READ MORE
2026/05/27
High‑Throughput MASH Animal Model Platform: Ready‑to‑Ship Solutions Empowering Rapid Preclinical Efficacy Assessment of Novel Therapeutics for Metabolic Diseases
Colleagues engaged in research and development in the field of metabolic diseases are well aware that, according to the consensus of the International Association for the Study of Liver Diseases, NASH (non‑alcoholic steatohepatitis) has been officially renamed MASH (metabolic dysfunction‑associated steatohepatitis). In our work on in vivo efficacy validation for MASH, the time required to establish the disease model is a critical factor—potentially even determining whether we can graduate on schedule.
2026/05/23
Science: How to Perform “Genetic Screening” on Astrocytes? In Vivo Single-Cell Library Screening Technology
The integration of single-cell RNA sequencing (scRNA-seq) with CRISPR‑based screening—known as Perturb‑seq—has revolutionized how we dissect gene function. However, in the context of intact, living tissues, efficiently and at scale investigating gain-of-function (GOF) effects remains fraught with technical challenges.
The integration of single-cell transcriptomics (scRNA-seq) with CRISPR‑based screening—known as Perturb‑seq—has revolutionized how we dissect gene function. However, in the context of intact, living tissues, efficiently and at scale investigating gain-of-function (GOF) effects remains fraught with technical challenges.
2026/05/20
Breakthrough: Successfully established an in vivo neuronal model of Alzheimer’s disease derived from iPSCs that spontaneously forms neurofibrillary tangles.
Tau protein primarily functions to stabilize the microtubule network within neurons. During transcription of the human MAPT (tau protein) gene, alternative splicing of exon 10 gives rise to multiple isoforms: 3R tau, which is produced from transcripts lacking exon 10 and contains three microtubule-binding repeats; and 4R tau, which results from inclusion of this exon and contains four repeats.
Tau protein primarily functions to stabilize the microtubule network within neurons. During transcription of the human MAPT (tau protein) gene, alternative splicing of exon 10 gives rise to multiple isoforms: 3R tau, which lacks exon 10 and encodes a transcript containing three microtubule-binding repeats; and 4R tau, which includes this exon and encodes a transcript with four repeats.
2026/05/15
A Novel Mechanism of Immunotherapy for Alzheimer’s Disease: Microglia-Mediated Targeted Clearance of Amyloid Plaques
The plaque‑clearing efficacy of amyloid‑targeted immunotherapies is highly dependent on microglial activation, yet this mechanism had previously lacked robust empirical support. At the recent International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) held in Copenhagen, Denmark, several studies have helped to fill this critical gap in our understanding of the underlying mechanisms.
The plaque‑clearing efficacy of amyloid‑targeting immunotherapies is highly dependent on microglial activation, yet this mechanism has previously lacked robust empirical support. At the recent Alzheimer’s & Parkinson’s Disease (AD/PD) International Conference held in Copenhagen, Denmark, several studies have helped to fill this critical gap in our understanding of the underlying mechanisms.